Hemostemix Inc (HEM) - Net Assets

Latest as of September 2025: CA$-3.46 Million CAD ≈ $-2.50 Million USD

Based on the latest financial reports, Hemostemix Inc (HEM) has net assets worth CA$-3.46 Million CAD (≈ $-2.50 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.34 Million ≈ $968.53K USD) and total liabilities (CA$4.80 Million ≈ $3.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check HEM asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$-3.46 Million
% of Total Assets	-258.5%
Annual Growth Rate	N/A
5-Year Change	N/A
10-Year Change	-4238.44%
Growth Volatility	895.94

Hemostemix Inc - Net Assets Trend (2013–2024)

This chart illustrates how Hemostemix Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Hemostemix Inc for the complete picture of this company's asset base.

Annual Net Assets for Hemostemix Inc (2013–2024)

The table below shows the annual net assets of Hemostemix Inc from 2013 to 2024. For live valuation and market cap data, see market cap of Hemostemix Inc.

Year	Net Assets	Change
2024-12-31	CA$-7.20 Million ≈ $-5.21 Million	+2.27%
2023-12-31	CA$-7.37 Million ≈ $-5.33 Million	-8.90%
2022-12-31	CA$-6.77 Million ≈ $-4.90 Million	-28.10%
2021-12-31	CA$-5.28 Million ≈ $-3.82 Million	-380.92%
2020-12-31	CA$-1.10 Million ≈ $-794.78K	+72.84%
2019-12-31	CA$-4.05 Million ≈ $-2.93 Million	-929.26%
2018-12-31	CA$487.80K ≈ $352.87K	-89.92%
2017-12-31	CA$4.84 Million ≈ $3.50 Million	+239.73%
2016-12-31	CA$-3.46 Million ≈ $-2.50 Million	-2088.88%
2015-12-31	CA$174.08K ≈ $125.93K	-94.86%
2014-12-31	CA$3.39 Million ≈ $2.45 Million	+490.67%
2013-12-31	CA$573.87K ≈ $415.13K	--

Equity Component Analysis

This analysis shows how different components contribute to Hemostemix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5150264900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Other Components	CA$58.68 Million	%
Total Equity	CA$-7.20 Million	100.00%

Hemostemix Inc Competitors by Market Cap

The table below lists competitors of Hemostemix Inc ranked by their market capitalization.

Company	Market Cap
Garovaglio y Zorraquin S.A. BA:GARO	$8.18 Million
Inter-Delta Tbk JK:INTD	$8.18 Million
Oceancash Pacific Bhd KLSE:0049	$8.18 Million
Avalon Holdings Corporation NYSE MKT:AWX	$8.19 Million
Eurasia Fonciere Investissements Société Anonyme PA:EFI	$8.17 Million
LabGenomics Co. Ltd KQ:084650	$8.17 Million
Axiom Properties Ltd AU:AXI	$8.17 Million
Pharmacielo Ltd V:PCLO	$8.16 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Hemostemix Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from -7,371,228 to -7,204,151, a change of 167,077.
Net loss of 2,616,402 reduced equity.
New share issuances of 2,452,496 increased equity.
Other comprehensive income decreased equity by 1,487,187.
Other factors increased equity by 1,818,170.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CA$-2.62 Million	-36.32%
Share Issuances	CA$2.45 Million	+34.04%
Other Comprehensive Income	CA$-1.49 Million	-20.64%
Other Changes	CA$1.82 Million	+25.24%
Total Change	CA$-	%

Book Value vs Market Value Analysis

This analysis compares Hemostemix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-12-31	CA$0.19	CA$0.06	x
2014-12-31	CA$1.09	CA$0.06	x
2015-12-31	CA$0.05	CA$0.06	x
2016-12-31	CA$-1.03	CA$0.06	x
2017-12-31	CA$0.69	CA$0.06	x
2018-12-31	CA$0.03	CA$0.06	x
2019-12-31	CA$-0.27	CA$0.06	x
2020-12-31	CA$-0.03	CA$0.06	x
2021-12-31	CA$-0.09	CA$0.06	x
2022-12-31	CA$-0.10	CA$0.06	x
2023-12-31	CA$-0.09	CA$0.06	x
2024-12-31	CA$-0.05	CA$0.06	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Hemostemix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 0.00%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 0.00x
Recent ROE (0.00%) is above the historical average (-336.28%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	-268.44%	0.00%	0.00x	1.42x	CA$-1.60 Million
2014	-127.82%	0.00%	0.00x	1.16x	CA$-4.67 Million
2015	-2289.23%	0.00%	0.00x	4.58x	CA$-4.00 Million
2016	0.00%	0.00%	0.00x	0.00x	CA$-3.44 Million
2017	-81.34%	0.00%	0.00x	1.10x	CA$-4.42 Million
2018	-1268.49%	0.00%	0.00x	3.41x	CA$-6.24 Million
2019	0.00%	0.00%	0.00x	0.00x	CA$-4.47 Million
2020	0.00%	0.00%	0.00x	0.00x	CA$-7.66 Million
2021	0.00%	0.00%	0.00x	0.00x	CA$-5.76 Million
2022	0.00%	0.00%	0.00x	0.00x	CA$-4.56 Million
2023	0.00%	0.00%	0.00x	0.00x	CA$-1.76 Million
2024	0.00%	0.00%	0.00x	0.00x	CA$-1.90 Million

Industry Comparison

This section compares Hemostemix Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $27,651,564
Average return on equity (ROE) among peers: -421.37%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Hemostemix Inc (HEM)	CA$-3.46 Million	-268.44%	N/A	$8.18 Million
Appili Therapeutics Inc (APLI)	$-13.40 Million	0.00%	0.00x	$1.86 Million
Aptose Biosciences Inc (APS)	$7.33 Million	-189.11%	0.18x	$4.36 Million
Arch Biopartners Inc (ARCH)	$1.06 Million	-79.15%	0.19x	$20.88 Million
Biomind Labs Inc (BMND)	$-1.30 Million	0.00%	0.00x	$6.98 Million
Cybin Inc (CYBN)	$237.20 Million	-47.70%	0.09x	$301.37 Million
Eupraxia Pharmaceuticals Inc (EPRX)	$1.18 Million	-3177.89%	21.71x	$393.86 Million
Devonian Health Group Inc (GSD)	$14.25 Million	-32.28%	0.35x	$20.01 Million
Helix BioPharma Corp. (HBP)	$-1.39 Million	0.00%	0.00x	$116.58 Million
Universal Ibogaine Inc (IBO)	$3.94 Million	-266.20%	0.60x	$1.13 Million

About Hemostemix Inc

V:HEM Canada Biotechnology

Market Cap

$8.18 Million

CA$11.31 Million CAD

Market Cap Rank

#27339 Global

#1183 in Canada

Share Price

CA$0.06

Change (1 day)

+0.00%

52-Week Range

CA$0.06 - CA$0.15

All Time High

CA$13.40